Core Viewpoint - XORTX Therapeutics Inc. has changed its auditor from Smythe LLP to Davidson & Company LLP effective January 16, 2025, with no reservations or reportable events noted during the transition [1][2][3]. Auditor Change - The board of directors accepted the resignation of the former auditor and appointed the successor auditor effective January 16, 2025, to serve until the next annual general meeting of shareholders [2]. - There were no reservations in the former auditor's reports for any financial period, and no reportable events occurred between the company and the former auditor [3]. Compliance and Documentation - The Notice of Change of Auditor and required letters from both auditors have been reviewed by the company's audit committee and board of directors, and filed on the company's SEDAR+ profile [4]. Company Overview - XORTX Therapeutics Inc. is focused on developing innovative therapies for progressive kidney disease and gout, with three clinically advanced products: XRx-008 for ADPKD, XRx-026 for allopurinol intolerant gout, and XRx-101 for acute kidney injury related to COVID-19 [5]. - The company also has a pre-clinical program, XRx-225, targeting Type 2 Diabetic Nephropathy, aiming to improve the quality of life for patients with kidney disease and gout [5].
XORTX Announces Change of Auditor